clinical trial · NCT06628908
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated·phase3·recruiting·n = 1,100
Diabetic Peripheral Neuropathic PainSuzetriginePlacebo (matched to SUZ)PregabalinPlacebo (matched to Pregabalin)
brief summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
started
Oct 1, 2024
primary completion
May 31, 2027
completion
May 31, 2027
last updated
Mar 31, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol